Development of a new immunostimulatory drug for non-haemolytic alternative to PQ.
| Project/Area Number |
18K19394
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 47:Pharmaceutical sciences and related fields
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
伊従 光洋 金沢大学, 薬学系, 准教授 (20608351)
|
|---|
| Project Period (FY) |
2018-06-29 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2019: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2018: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 三日熱マラリア / プリマキン / 自然免疫 / バキュロウルス / マラリア / バキュロウイルス / インターフェロン / ヒプノゾイト |
|---|
| Outline of Final Research Achievements |
Baculovirus (BV)-induced innate immunity completely kills liver-stage parasites using IFN-aRKO and IFN-gRKO mice. As primaquine (PQ) is the only licensed drug for the radical cure of P. vivax hypnozoites, we compared the elimination effects of BV with those of PQ. Treatment with PQ could not exclude liver-stage parasites. Treatment with BV proves to be more effective than PQ. BV effectively induces fast-acting innate immune responses that provide powerful first lines of both defensive and offensive attacks against pre-erythrocytic parasites. Our results illustrate the potential of BV as a new potent prophylactic and therapeutic immunostimulatory agent against pre-erythrocytic stage parasites.
|
| Academic Significance and Societal Importance of the Research Achievements |
三日熱マラリアの根治治療に使用されている唯一の薬プリマキンは、多くの禁忌、副作用があり三日熱マラリアコントロールの障害となっている。BVが誘導する自然免疫応答が肝臓期マラリア原虫に対して強力な殺傷効果を発揮するメカニズムを一部解明できたことは、BVを利用したプリマキンに替わる新しいコンセプトの抗マラリア新薬の開発につながる。
|
Report
(3 results)
Research Products
(38 results)
-
-
-
-
-
[Journal Article] A Viral-Vectored Multi-Stage Malaria Vaccine Regimen With Protective and Transmission-Blocking Efficacies2019
Author(s)
Yusuf Y, Yoshii T, Iyori M, Mizukami H, Fukumoto S, Yamamoto DS, Emran TB, Amelia F, Islam A, Syafira I, Yoshida S.
-
Journal Title
Front Immunol
Volume: 10
Pages: 2412-2412
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming2019
Author(s)
Yusuf Y, Yoshii T, Iyori M, Yoshida K, Mizukami H, Fukumoto S, Yamamoto DS, Alam A, Emran TB, Amelia F, Islam A, Otsuka H, Takashima E, Tsuboi T, Yoshida S.
-
Journal Title
Frontiers in Immunology
Volume: 10
Pages: 730-730
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
[Journal Article] Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.2018
Author(s)
Yoshida K, Iyori M, Blagborough AM, Salman AM, Dulal P, Sala KA, Yamamoto DS, Khan SM, Janse CJ, Biswas S, Yoshii T, Yusuf Y, Tokoro M, Hill AVS, Yoshida S
-
Journal Title
Scientific Reports
Volume: 8
Issue: 1
Pages: 3896-3896
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Baculovirus-Induced Fast-Acting Innate Immunity Kills Liver-Stage Plasmodium.2018
Author(s)
Emran TB, Iyori M, Ono Y, Amelia F, Yusuf Y, Islam A, Alam A, Tamura M, Ogawa R, Matsuoka H, Yamaoto DS, Yoshida S.
-
Journal Title
The Journal of Immunology
Volume: 201
Issue: 8
Pages: 2441-2441
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Development of a novel malaria vaccine based on heterologous prime-boost immunization regimen using adenovirus and adeno-associated virus vectors2018
Author(s)
Iyori M, Yoshida K, Yusuf Y, Emran TB, Yoshii T, Hashizume H, Shimada S, Yamamoto DS, Fukumoto S, Mizukami H, Yoshida S
Organizer
14th International congress of parasitology
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
